Biogen Idec will present more than 50 company-sponsored platform and poster presentations on data supporting its multiple-marketed and pipeline therapies for neurological diseases at the 65th American Academy of Neurology (AAN) Annual Meeting in San Diego, March 16-23, 2013.
dctrig.....I am starting to regret selling all my shares now that it's starting to pop a few pennies. It was a gutsy call, profitted $2200....if it goes back down I may jump back in. If not......hope it shoots up for the ones who are init.
Most small biotechs at the $1 mark get attacked incessantly and most fall and stay below $1: however, market makers are not letting the bullies get ultra-cheap shares.There are just too may upcoming meetings and potential catalysts